Adalimumab for the treatment of hidradenitis suppurativa/acne inversa

References

• Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–164.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–190.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455–472.
   PubMed Web of Science ®Google Scholar
• Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9–16.
   PubMedGoogle Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.
   PubMed Web of Science ®Google Scholar
• Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–419.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa /acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–644.
   PubMed Web of Science ®Google Scholar
• McMillan K. Diagnoses of hidradenitis suppurativa in the United States, 1979–2012. Skin Appendage Disord. 2015;1:117–122.
   PubMedGoogle Scholar
• Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(suppl 1):S4–S7.
   Google Scholar
• Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Tsatsou F. Disorders of the apocrine sweat glands. In: Goldsmith LA, Katz SI, Gilchrest BA, et al., editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York (NY): McGrawHill; 2012. p.947–959.
   Google Scholar
• Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–1549.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831–839.
   PubMed Web of Science ®Google Scholar
• Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–824.
   PubMed Web of Science ®Google Scholar
• Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553–557.
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–623.
   PubMed Web of Science ®Google Scholar
• Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62:706–708.
   PubMed Web of Science ®Google Scholar
• Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain. 2010;26:435–444.
   PubMed Web of Science ®Google Scholar
• Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27:473–478.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90:264–268.
   PubMed Web of Science ®Google Scholar
• Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67:422–428.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328–332.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Bechara FG, Fritz K, et al. S1 – Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10 Ziffer: L73.2). J Dtsch Dermatol Ges. 2012;10(Suppl5):S1–S31.
   Google Scholar
• Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533–537.
   PubMed Web of Science ®Google Scholar
• Kelly G, Sweeney CM, Tobin A-M, et al. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53:1186–1196.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601–603.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–1298.
   PubMed Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–374.
   PubMed Web of Science ®Google Scholar
• Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk HH Jr, editors. Dermatologic surgery. Principles and practice. 2nd ed. New York (NY): Marcel Dekker; 1996. p. 623–645.
   Google Scholar
• Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186:1228–1239.
   PubMed Web of Science ®Google Scholar
• Mozeika E, Pilmane M, Nürnberg BM, et al. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol. 2013;93:301–304.
   PubMed Web of Science ®Google Scholar
• Emelianov VU, Bechara FG, Glaser R, et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol. 2012;166:1023–1034.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166:298–305.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol. 2007;156:51–56.
   PubMed Web of Science ®Google Scholar
• Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148:182–186.
   PubMedGoogle Scholar
• Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73(suppl 1):S82–S88.
   Google Scholar
• van Rappard DC, Mekkes JR, Tzellos T. Randomized controlled trials for the treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34:69–80.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab treatment of hidradenitis suppurativa. N Engl J Med. 2016;375:422–434.
   PubMed Web of Science ®Google Scholar
• Machold KP, Smolen JS. Adalimumab - a new TNF-α-antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther. 2003;3:351–360.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Granneman RG, Zhang Y, Noertersheuser PA, et al. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum. 2003;48:S140−1.
   Web of Science ®Google Scholar
• Kaymakcalan Z, Beam C, Salfeld J. Murine model for assessing adalimumab, infliximab, and etanercept to prevent polyarthritis. Ann Rheum Dis. 2003;62(suppl 1):136−7.
   Google Scholar
• Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34:19−22.
   PubMed Web of Science ®Google Scholar
• Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65:746−52.
   PubMed Web of Science ®Google Scholar
• Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol. 2002;38:1073−83.
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52:2693−6.
   PubMed Web of Science ®Google Scholar
• Kohno T, Tam L, Ting T, et al. Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. Arthritis Rheum. 2005;52:S562−3.
   Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Adalimumab, etanercept, and infliximab bind to soluble and transmembrane TNF with similar affinities. Ann Rheum Dis. 2006;65(supplII):458.
   Google Scholar
• Kohno T, Louie JS, Stevens SR. Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J Invest Dermatol. 2005;124:A111.
   PubMedGoogle Scholar
• Maurice MM, Van Der Graaff WL, Leow A, et al. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:2166−2173.
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Apalla Z, Vakirlis E, et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19:180–181.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol. 2009;8:181–183.
   PubMed Web of Science ®Google Scholar
• Bahillo Monné C, Honorato Guerra S, Schoendorff Ortega C, et al. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature. Dermatology. 2014;229:279–287.
   PubMed Web of Science ®Google Scholar
• Chinniah N, Cains GD. Moderate to severe hidradenitis suppurativa treated with biological therapies. Australas J Dermatol. 2014;55:128–131.
   PubMed Web of Science ®Google Scholar
• Zhang J, Reeder J, Hamzavi H. Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience. Br J Dermatol. 2014;171:1600–1602.
   PubMed Web of Science ®Google Scholar
• Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28:158–165.
   PubMed Web of Science ®Google Scholar
• Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:56–60.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Hotz C, Seneschal J, et al. Antitumor necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. Br J Dermatol. 2016;174:667–670.
   PubMed Web of Science ®Google Scholar
• Blanco R, Martínez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580–584.
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49:1445–1449.
   PubMed Web of Science ®Google Scholar
• Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49:950–955.
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11:s15–S20.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–398.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846–855.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebocontrolled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989–994.
   PubMed Web of Science ®Google Scholar
• Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89:595–600.
   PubMed Web of Science ®Google Scholar
• Blok JL, van Hattem S, Jonkman MF, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–252.
   PubMed Web of Science ®Google Scholar
• van Rappard DC, Leenarts MF, Meijerink-van’t Oost L, et al. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012;23:284–289.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–217.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–213.
   PubMed Web of Science ®Google Scholar
• Revuz J. Modifications et mode d’emploi du score de Sartorius pour évaluer la gravité de l’hidradénite suppurée. Ann Dermatol Venereol. 2007;134:173–174.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;10:CD010081.
   Google Scholar
• Zouboulis CC, Okun MM, Gniadecki R, et al. Adalimumab efficacy in hidradenitis suppurativa patients is sustained at least two years with weekly dosing: results from a phase 3 open-label extension study (PIONEER). Abstract, 25th EADV Congress; 2016; Sep 28–Oct 10; Vienna, Austria.
   Google Scholar
• Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153–1159.
   PubMed Web of Science ®Google Scholar
• Delobeau M, Abdou A, Puzenat E, et al. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. J Dermatol Treat. 2016;27:251–253.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. Partial actualization of the European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Exp Dermatol. 2016;25(suppl 2):13.
   Google Scholar
• Zouboulis CC, Alavi A, Bettoli V, et al. Hidradenitis suppurativa severity score system (HS4): preliminary results. Exp Dermatol. 2016;25(suppl 2):5.
   Google Scholar